Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Crowd sourcing in drug discovery

Nature Reviews Drug Discovery volume 10, pages 241–242 (2011)Cite this article

Subjects

Abstract

Crowd sourcing is emerging as an open-innovation approach to promote collaboration and harness the complementary expertise of academic and industrial partners in the early stages of drug discovery. Here, we highlight examples of such initiatives and discuss key success factors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug. Discov. 9, 203–214 (2010).

    Article  CAS  Google Scholar 

  2. Howe, J. (ed.) Crowdsourcing: Why the Power of the Crowd is Driving the Future of Business. (Crown Publishing Group, New York, 2008).

  3. Lessl, M. et al. Grants4Targets — a novel approach to translate basic research to novel drugs. Drug Discov. Today 1 Dec 2010 (doi:10.1016/j.drudis.2010.11.013).

  4. Bishop, M. The total economic impact of InnoCentive's enterprise solution: challenges, InnoCentive@work and ONRAMP. (Forrester Business Consulting, Cambridge, Massachusetts, 2010).

    Google Scholar 

Download references

Acknowledgements

The authors thank S. Schoepe for her valuable contributions in editing the manuscript.

Author information

Authors and Affiliations

  1. Monika Lessl and Khusru Asadullah are at Global Drug Discovery Bayer HealthCare Pharmaceuticals, Muellerstraße 178, 13342 Berlin, Germany,

    Monika Lessl & Khusru Asadullah

  2. Justin. S. Bryans is at the Centre for Therapeutics Discovery, MRC Technology, 1–3 Burtonhole Lane, London NW7 1AD, UK,

    Justin S. Bryans

  3. Duncan Richards is at GlaxoSmithKline, Academic Discovery Performance Unit, Medicines Research Centre, Stevenage SG1 2NY, UK,

    Duncan Richards

Authors
  1. Monika Lessl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justin S. Bryans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Duncan Richards
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Khusru Asadullah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Lessl.

Ethics declarations

Competing interests

Monika Lessl and Khusru Asadullah are employees of Bayer HealthCare Pharmaceuticals. Duncan Richards is an employee at GlaxoSmithKline. Justin. S. Bryans does not declare any competing financial interests.

Supplementary information

Supplementary information Table S1

Examples of novel crowd sourcing initiatives in drug discovery (PDF 249 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lessl, M., Bryans, J., Richards, D. et al. Crowd sourcing in drug discovery. Nat Rev Drug Discov 10, 241–242 (2011). https://doi.org/10.1038/nrd3412

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3412

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research